A
Ablatherm device 243
Aerobic glycolysis 22
Alpha-blockers 375
American Society for Therapeutic Radiology and Oncology (ASTRO)
on biochemical recurrence after radiation therapy 67
criteria, prostate cancer 47
on radiorecurrent prostate cancer 281
American Urological Association (AUA)
on nephron-sparing surgery for small renal masses 337
prostate cancer, guidelines on 53
Angioembolization (AE), for bleeding 370
Angiogenesis 21
ASTRO see American Society for Therapeutic Radiology and Oncology (ASTRO)
AUA see American Urological Association (AUA)
Autophagy 22
B
Biomarkers, prostate cancer 91 see also specific biomarkers
phases of development 92
requirements for 92
types of 93
Bleeding, focal treatment of renal cancer and
kidney function, effects on 372
BPH see Benign prostatic hyperplasia (BPH)
Breast cancer
radical mastectomy vs. breast-conserving lumpectomy 4
Breast conserving therapy (BCT) 4
C
Cancer of the Prostate Strategic Urological Research Endeavor (CaPSURE), on radical prostatectomy 56
Carey index 312
Cavitation 241
Cell cycle progression (CCP) score 101
C-index see Centrality index (C-index)
CKD see Chronic kidney disease (CKD)
Comprehensive geriatric assessment (CGA) 311
Curietherapy see Brachytherapy
D
Digital rectal examination (DRE) 6
Dynamic contrast-enhanced MR imaging (DCE-MRI), in prostate mpMRI 165
E
European Association of Urology (EAU) guidelines, on focal therapy for renal cancer 306
European Organization for Research and Treatment of Cancer (EORTC QLQ-C-30) 58
EXO106 assay 95
Exosome analysis 95
Expanded Prostate Cancer Index Composite (EPIC) 80
F
Fluorescence in situ hybridization (FISH) assay 98
advantages of 201
correct sequence for placing laser fiber into lesion 204
mechanism of tissue destruction 198
patient preparation 202
patient selection 206
system components 200
Focal prostate cancer therapy 267
Focal prostate laser ablation (FPLA) see Laser interstitial thermotherapy
Future directions in focal therapy 49
Formalin-fixed paraffin-embedded (FFPE) needle biopsy 101
H
focal therapy and 62
radiation vs. surgery 56
surgery vs. observation 56
whole gland therapy, and focal therapy 63
Hematuria, cryotherapy and 193
Hem-o-Lok clips 323
Hernia, after renal focal ablation 373
I
IGA see Image-guided ablation (IGA)
Immunohistochemical (IHC) assay 98
Immunosuppressive agents, by cancer cells 22
Interstitial laser therapy see Laser therapy
M
Magnetic resonance-guided focused ultrasound (MRgFUS) ablation 156
Magnetic resonance imaging, for renal tumors 123
MI-Prostate Score 95
Mount Sinai Erectile Function (MSEF) scoring system 60
mpMRI see Multiparametric magnetic resonance imaging (mpMRI)
MRI-targeted biopsy 170
Multidetector computed tomography (CT), for renal mass 123
MWA see Microwave ablation (MWA)
N
Necrosis 22
NeuroBlate system (laser system) 200
Novilase system (laser system) 200
Nuclear imaging, for small renal tumor 124
P
Pancreatic injuries, renal focal therapy and 373
Paresthesia, renal focal ablation and 377
PDT see Photodynamic therapy (PDT)
Phoenix criteria, definition for radiorecurrent prostate cancer 281
Photodynamic therapy (PDT) 27
interstitial (iPDT) 214
vascular-targeted (see Vascular-targeted photodynamic (VTP) therapy)
Pleural injury, renal focal therapy and 373
combining biopsy and clinical parameters 155
Prostate cancer (PCa) 53
in-field/out-of-field residual/recurrent disease 294
localized 43
percent of tumor involvement (PTI) 7
potential hemiablation of prostate, concept of 8
risk calculators for 42
screening for 6
trend toward smaller volume of disease 7
TRUS biopsies for, concerns with 44
tumor unilaterality 8
Prostate Core Mitomic Test (PCMT) 98
Prostate health index (PHI) 96
PSM see Positive surgical margin (PSM)
R
Radiation, internally delivered see Brachytherapy
Radical nephrectomy (RN) 139
functional outcomes 86
hemostasis control after dorsal vein complex transection 74
ligation of dorsal vein complex 72
open salvage, outcomes of 71
patient positioning and initial incision 70
pelvic lymph node dissection 70
and radiation therapy 56
transection of dorsal vein complex 73
urethrovesical anastomosis 82
adjunctive therapy with 26
of breast cancers 25
and cryosurgery 33
of kidney tumors 25
of liver tumors 25
RAPN see Robot-assisted partial nephrectomy (RAPN)
Rectourethral fistula, development of 272
Renal biopsies 315
chromophobe 111
clear cell RCC 111
incidental detection of 110
origin of 110
papillary RCC 111
radical nephrectomy for 5
risk factors for 111
small renal masses, detection of 5
Renal cell carcinomas (RCC) see Renal cancer
Retrograde ejaculation 194
RFA see Radiofrequency ablation (RFA)
Robot-assisted laparoscopic prostatectomy (RALP), salvage 76
readmission rate 332
RP see Radical prostatectomy (RP)
S
cryoablation, local recurrence after 384
high intensity focused ultrasound, local recurrence after 384
Satellite lesions, role of 12
SBRT see Stereotactic radiation therapy (SBRT)
Senescence 21
Sexual Health Inventory for Men 80
Short Form (SF-12) 58
Sonablate device 243
Spleen, injury to, renal focal therapy and 373
SRMs see Small renal masses (SRMs)
dose distributions plan 258
T
Telomerases, in cancer cells 22
Template-mapping biopsies 44
Testicular swelling, cryotherapy and 193
TMB see Transperineal mapping biopsy (TMB)
TOOKAD Soluble VTP procedure see Vascular-targeted photodynamic (VTP) therapy
Bard biopsy device, use of 178
Tumor biology, of prostate cancer
secondary satellite lesions, role of 12
Tumorigenesis 9
Tumor-seeding 378
V
phase-change in 232
Vascular-targeted photodynamic (VTP) therapy 214 see also Photodynamic therapy (PDT)
contraindications to 216
mechanism of action 213
phase III studies 222
diaphragmatic injuries and pneumothorax 373
spleen and pancreatic injuries 373
ureteral injuries 373
Visualase system (laser system) 200
VTP therapy see Vascular-targeted photodynamic (VTP) therapy